{"filing":{"accession_number":"0001437749-26-022415","cik":"0001016504","ticker":"INBP","company_name":"INTEGRATED BIOPHARMA INC","form":"8-K","filing_date":"2026-07-02","report_date":null,"primary_document":"inbp20260630_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1016504/000143774926022415/inbp20260630_8k.htm"},"events":[{"id":15746,"run_id":14041,"accession_number":"0001437749-26-022415","anchor_item_number":"1.01","event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.85,"summary":"The Company entered into a First Amendment extending its revolving line of credit to April 14, 2027, and simultaneously created a new Convertible Line of Credit Note (Convertible ELOC) for $250,000 with PNC Bank, replacing a prior $500,000 Convertible Equipment Line of Credit Note. These amendments and new issuances represent material changes to the Company's direct financial obligations and capital structure.","company_name":"INTEGRATED BIOPHARMA INC","ticker":"INBP","filing_date":"2026-07-02","form":"8-K","submitted_at":null,"items":[{"id":13634,"accession_number":"0001437749-26-022415","item_number":"1.01","item_title":"ENTRY INTO A MATERIAL DEFINITIVE AGREEMENT.","event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"The Company entered into a First Amendment extending its revolving line of credit to April 14, 2027, and simultaneously created a new Convertible Line of Credit Note (Convertible ELOC) for $250,000 with PNC Bank. These represent new or materially amended direct financial obligations. While the revolving line was previously in place, the amendment extends its term and the new Convertible ELOC is a distinct debt instrument, making this a debt issuance event under Item 1.01.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-02T14:38:39.451414+00:00","company_name":"","ticker":null,"filing_date":""},{"id":13635,"accession_number":"0001437749-26-022415","item_number":"1.02","item_title":"TERMINATION OF A MATERIAL DEFINITIVE AGREEMENT.","event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.72,"reasoning":"The filing discloses termination of a $500,000 Convertible Equipment Line of Credit Note and its replacement by a new Convertible ELOC. While Item 1.02 formally addresses termination, the substance is a refinancing or replacement of a material debt facility. The convertible feature and the explicit reference to a replacement instrument suggest this is a material capital event affecting the registrant's financial obligations and equity structure.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-02T14:38:39.451414+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":13634,"accession_number":"0001437749-26-022415","item_number":"1.01","item_title":"ENTRY INTO A MATERIAL DEFINITIVE AGREEMENT.","event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"The Company entered into a First Amendment extending its revolving line of credit to April 14, 2027, and simultaneously created a new Convertible Line of Credit Note (Convertible ELOC) for $250,000 with PNC Bank. These represent new or materially amended direct financial obligations. While the revolving line was previously in place, the amendment extends its term and the new Convertible ELOC is a distinct debt instrument, making this a debt issuance event under Item 1.01.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-02T14:38:39.451414+00:00","company_name":"INTEGRATED BIOPHARMA INC","ticker":"INBP","filing_date":"2026-07-02"},{"id":13635,"accession_number":"0001437749-26-022415","item_number":"1.02","item_title":"TERMINATION OF A MATERIAL DEFINITIVE AGREEMENT.","event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.72,"reasoning":"The filing discloses termination of a $500,000 Convertible Equipment Line of Credit Note and its replacement by a new Convertible ELOC. While Item 1.02 formally addresses termination, the substance is a refinancing or replacement of a material debt facility. The convertible feature and the explicit reference to a replacement instrument suggest this is a material capital event affecting the registrant's financial obligations and equity structure.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-02T14:38:39.451414+00:00","company_name":"INTEGRATED BIOPHARMA INC","ticker":"INBP","filing_date":"2026-07-02"}]}